Rochester, Minnesota 55905


Purpose:

The purpose of this study is to explore the detection of circulating tumor DNA, soluble immune markers, and the evaluation of peripheral blood mononuclear cells (PBMC).


Study summary:

Our plan is to collect blood from patients with advanced stage lung cancer who are scheduled to undergo systemic therapy. In this study we will utilize a novel technology for circulating tumor DNA detection in order to evaluate their presence in patients with lung cancer by comparing blood samples at six time points. We will obtain baseline blood and then collect blood at five time points during the course of the patient's chemotherapy treatments and at the end of treatment. These same blood collections will be used for the detection of soluble immune markers and evaluation of PBMCs.


Criteria:

Inclusion Criteria: - Advanced (non-resectable) malignancy in the thorax - Age >18 years old - Willing and able to provide consent - No prior history of neoadjuvant therapy Exclusion Criteria: - Age <18 years old - Unable to provide consent - Patients with hemoglobin less than 10 g/dL (to minimize the impact of potential iatrogenic anemia)


NCT ID:

NCT02410603


Primary Contact:

Principal Investigator
Aaron Mansfield, MD
Mayo Clinic

Karlyn Pierson, RN
Phone: 507-538-1960
Email: pierson.karlyn@mayo.edu


Backup Contact:

Email: lechtenberg.bettie@mayo.edu
Bettie Lechtenberg, MBA
Phone: 507-266-4819


Location Contact:

Rochester, Minnesota 55905
United States

Karlyn Pierson, RN
Phone: 507-538-1960
Email: pierson.karlyn@mayo.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.